ArticleNature2020
IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 77 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Gene expression profiling of host lipid metabolism in SARS-CoV-2 infected patients: a systematic review and integrated bioinformatics analysis.BMC infectious diseases · 2024Pooled it
- Interferon-induced transmembrane protein 3 gene polymorphisms are associated with COVID-19 susceptibility and severity: A meta-analysis.The Journal of infection · 2022Pooled it
- Article
- Interferon-induced transmembrane (IFITM) proteins at the tumour-immune interface: A four-axis framework for their context-dependent roles.Clinical and translational medicine · 2026Review
- Cholesterol Drives IFITM3CNS neuroscience & therapeutics · 2026Article
- Interferon-induced transmembrane proteins in cancer and virus biology: a membrane perspective.mBio · 2026Review
- Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.Blood advances · 2026Article
- IFN-gene signatures in B cells following influenza A and B virus infection and influenza vaccination.EMBO molecular medicine · 2026Article
- Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia.Science signaling · 2026Article
- Review
- Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma.Science advances · 2025Article
- KAL suppresses cholangiocarcinoma growth via downregulating miR-21 and modulating the PTEN/AKT signaling pathway.Scientific reports · 2025Article
- IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.Molecular cancer · 2025Article
- Identification and antiviral mechanism of a novel chicken-derived interferon-related antiviral protein targeting PRDX1.PLoS pathogens · 2025Article
- STAT1-IFITM3 promotes autophagy in epithelial cells to controlLife science alliance · 2025Article
- IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route.Vaccine · 2025Article
- Review
- IFITM2 Modulates Endocytosis Maintaining Neural Stem Cells in Developing Neocortex.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- From defense to disease: IFITM3 in immunity and Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Immune pathogenic response landscape of acute posterior multifocal placoid pigment epitheliopathy revealed by scRNA sequencing.Genes and immunity · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
29 authors at 10 institutions in 2 countries.
Jaewoong LeeCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Mark E RobinsonCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2363-6047
Ning MaDepartment of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Dewan ArtadjiCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-1189-6936
Mohamed A AhmedDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-4476-0768
Gang XiaoDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Teresa SadrasCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Gauri DebDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Janet WinchesterDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Kadriye Nehir CosgunCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Huimin GengDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Lai N ChanCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Kohei KumeCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2856-5970
Teemu P MiettinenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5975-200X
Ye ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Matthew A NixDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7741-5368
Lars KlemmCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Chun Wei ChenDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-8737-6830
Jianjun ChenDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-3749-2902
Vishal KhairnarDepartment of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Arun P WiitaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7465-6964
Andrei Thomas-TikhonenkoDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael FarzanDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.ORCID http://orcid.org/0000-0002-2990-5319
Jae U JungDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-4559-8774
David M WeinstockDana Farber Cancer Institute, Boston, MA, USA.
Scott R ManalisKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5223-9433
Michael S DiamondDepartment of Medicine, Washington University School of Medicine in St Louis, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-8791-3165
Nagarajan VaidehiDepartment of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-8100-8132
Markus MüschenCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA. markus.muschen@yale.edu.ORCID http://orcid.org/0000-0002-6064-8613
City of Hope · USYale Cancer Center · USUniversity of California, San Francisco · USMassachusetts Institute of Technology · USChildren's Hospital of Philadelphia · USCleveland Clinic Lerner College of Medicine · USHarvard University · USMRC Laboratory for Molecular Cell Biology · GBScripps Research Institute · USWashington University in St. Louis · US
Funding
Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MTR&D 7: Cell Specific ProteomicsP41GM108569 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2015 to 2024
$13.6MMetabolic gatekeepers in B-cell malignanciesR35CA197628 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2016 to 2026
$11.7MQuantitative and functional characterization of therapeutic resistance in cancerU54CA217377 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAUFFENBURGER, DOUGLAS A, MANALIS, SCOTT R · 2017 to 2021
$10.2MTargeting oncogenic TCR signaling in PTCLP01CA233412 · NCI · DANA-FARBER CANCER INST · PI KNOECHEL, BIRGIT · 2019 to 2023
$8.7MMolecular Basis of KSHV oncogenesisR35CA200422 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2016 to 2022
$6.1MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MKSHV Epigenetic RegulationR01DE023926 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2013 to 2024
$4.2MSFTSV nonstructural protein NSs-mediated immunopathogenesisR01AI140705 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2018 to 2022
$4.2MGenetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKVR01AI140718 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG, JUNG, JAE U · 2018 to 2022
$3.8MStructural dynamics underlying GPCR-G protein selectivityR01GM117923 · NIGMS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI VAIDEHI, NAGARAJAN · 2017 to 2024
$3.8MInnate Immune Control of West Nile VirusR01AI104002 · NIAID · UNIVERSITY OF WASHINGTON · PI DIAMOND, MICHAEL S, GALE, MICHAEL · 2013 to 2017
$3.7MHoward Hughes Medical InstituteNCI NIH HHS P01 CA233412NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA157644NCI NIH HHS R01 CA213138NCI NIH HHS R01 CA251275NCI NIH HHS R35 CA197628NCI NIH HHS R35 CA200422NCI NIH HHS R35 CA231958NCI NIH HHS U01 CA232563NCI NIH HHS U54 CA217377NIAID NIH HHS R01 AI104002NIAID NIH HHS R01 AI116585NIAID NIH HHS R01 AI127513NIAID NIH HHS R01 AI140705NIAID NIH HHS R01 AI140718NIDCR NIH HHS R01 DE023926NIDCR NIH HHS R01 DE028521NIGMS NIH HHS P41 GM108569NIGMS NIH HHS R01 GM097261NIGMS NIH HHS R01 GM117923NIH HHS AI116585NIH HHS AI116585SNIH HHS AI140705NIH HHS AI140718NIH HHS DE023926NIH HHS DE028521NIH HHS S10 OD025194NLM NIH HHS R01 LM013876Wellcome TrustWellcome Trust 110275/Z/15/Z
Abstract
Interferon-induced transmembrane protein 3 (IFITM3) has previously been identified as an endosomal protein that blocks viral infection
Indexed as
Signal TransductionAnimalsAntigens, CD19B-LymphocytesCell Transformation, NeoplasticFemaleGerminal CenterHumansIntegrinsMembrane MicrodomainsMembrane ProteinsMiceMice, Inbred C57BLMice, Inbred NODModels, MolecularPhosphatidylinositol 3-KinasesAntigens, CD19IFITM3 protein, humanIntegrinsMembrane Proteinsphosphatidylinositol 3,4,5-triphosphatePhosphatidylinositol 3-KinasesPhosphatidylinositol PhosphatesReceptors, Antigen, B-CellRNA-Binding Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.